TriangleNCT02823327 · REGISTRY CONDITION SEARCH
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- Not reported
- Status at capture
- TERMINATED
- Registry last update
- 2025-05-11
This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the laboratory may help doctors learn about the prognosis of patients with AIDS-related primary effusion lymphoma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or after January 1, 1998 on whom survival status at 2 years post PEL diagnosis is available * Participants may be enrolled to either or both the clinical or genomic portions of the study * The minimum data required to be able to include a subject for analysis of clinical prognostic factors are: * HIV status, and for HIV subjects include cluster of differentiation (CD)4 count, HIV viral load closest to time of diagnosis * Age at PEL diagnosis * Gender * Stage at diagnosis * Treatment of PEL * Response to treatment * Survival status at 2 years * Pathology slides (or paraffin block) for central review * The minimum data required to be able to include a subject for analysis of genomic prognostic factors are: * Availability of a pathologic specimen of PEL that will be submitted for genomic analysis * Survival status at 2 years Exclusion Criteria: * Patients who do not fulfill the criteria as listed above are ineligible
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sampling Method
- NON_PROBABILITY_SAMPLE
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
- study Population
- Participants diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or after January 1, 1998 and on whom survival status at 2 years post diagnosis is available.
Treatment arms and interventions
- arm Groups
- description
- Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
- intervention Names
- Genetic: Laboratory Biomarker Analysis
- Other: Medical Chart Review
- label
- Chart review, RNA sequencing, microarray
- interventions
- arm Group Labels
- Chart review, RNA sequencing, microarray
- description
- Correlative studies
- name
- Laboratory Biomarker Analysis
- type
- GENETIC
- arm Group Labels
- Chart review, RNA sequencing, microarray
- description
- Medical chart review is performed
- name
- Medical Chart Review
- other Names
- Chart Review
- type
- OTHER
Study design
- observational Model
- CASE_ONLY
- time Perspective
- RETROSPECTIVE
Enrollment
- count
- 25
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The resultant data will be a subset of the whole analysis population due to RNAseq data availability. It will be assessed for quality, normalized, and then analyzed for differential gene expression. The Nanostring software nSolver will be used to do quality control, background subtraction, normalization, and analysis of the differential expression for RNA-sequencing data. Lastly, bioinformatic analysis approaches will be used to help make sense of possible biological links between the genes found to be differentially expressed between the sample groups that may be of prognostic significance. 19 Genes with p-value less than 0.05 were reported by the level of gene expression.
- measure
- Differential Gene Expression Profile by RNA-Seq or GeneChip Assays
- time Frame
- baseline
- description
- The number of participants for this outcome measure is 25 participants with baseline characteristics and response evaluation. Since this was a retrospective study, response criteria were not defined. Response determinations as recorded in the medical record by the treating physician were abstracted on each participant for data analysis. Response rates will be reported with 95% confidence intervals (binomial distribution). Descriptive statistics will be used to summarize baseline clinical, histological, and viral characteristics.
- measure
- Response Rates
- time Frame
- Up to 1 year
- description
- Survival duration will be determined using the elapsed time between the date of PEL diagnosis and the last follow-up date or the date of death.
- measure
- Survival Status at 2 Years
- time Frame
- At 2 years post diagnosis
Full study description
- brief Summary
- This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the laboratory may help doctors learn about the prognosis of patients with AIDS-related primary effusion lymphoma.
- detailed Description
- PRIMARY OBJECTIVES: I. Identify baseline clinical characteristics and treatment strategies in patients with AIDS-associated primary effusion lymphoma (PEL) that correlate with long-term survival (\>= 2 years). (Primary clinical objective) II. Identify differentially expressed genes in PEL that are associated with long-term survival (\>= 2 years). (Primary genomic objective) OUTLINE: Medical chart review is performed and patient information is collected regarding human immunodeficiency virus human immunodeficiency virus (HIV)/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via ribonucleic acid (RNA) sequencing and microarray.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-2f020a6db738ce559587
- requested nct id
- NCT02823327
- primary nct id
- NCT02823327
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
- payload sha256
- 15a0ece385f5e3f485a4270a456ece934f556d42fcdcd952d562c88ae5a90d7d
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-2f020a6db738ce559587
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT02823327
- occurrences
- context exact
- NCT02823327
- end
- 11
- exact text
- NCT02823327
- start
- 0
- offset unit
- unicode_code_points
- query cond
- AIDS-Related Lymphoma
- query disease state id
- ds-aids-related-lymphoma
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-aids-related-lymphoma-000.json
- source file sha256
- a8469a8cca20a75ce4fa980eaab4ff20f62c99f2a2e732f1bd42590d1d5dbe14
- source json pointer
- /studies/13/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fbcbe83d2acfb619a9ea1b15eb9416bd503d88f8cd7a4e1df3a0bd71a6d21a84
Preserved source evidence · Not medical advice